Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

Journal of translational medicine - 20 Apr 2010

Søndergaard Jonas N, Nazarian Ramin, Wang Qi, Guo Deliang, Hsueh Teli, Mok Stephen, Sazegar Hooman, MacConaill Laura E, Barretina Jordi G, Kehoe Sarah M, Attar Narsis, von Euw Erika, Zuckerman Jonathan E, Chmielowski Bartosz, Comin-Anduix Begoña, Koya Richard C, Mischel Paul S, Lo Roger S, Ribas Antoni

Abstract excerpt

Blocking oncogenic signaling induced by the BRAFV600E mutation is a promising approach for melanoma treatment. We tested the anti-tumor effects of a specific inhibitor of Raf protein kinases, PLX4032/RG7204, in melanoma cell lines. PLX4032 decreased signaling through the MAPK pathway only in cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Diagnostic Imaging
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Sulfonamides

Share to Vemurafenib

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 20406486
DOI: 10.1186/1479-5876-8-39
PMCID: PMC2876068

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20406486-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.PMID 20406486Read ↗

Pharmacodynamic Characterization of the Efficacy Signals Due to Selective BRAF Inhibition with PLX4032 in Malignant MelanomaSemantic proximity Read ↗

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.Semantic proximity Read ↗

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.Semantic proximity Read ↗

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors.Semantic proximity Read ↗

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.Semantic proximity Read ↗

Inhibition of mutated, activated BRAF in metastatic melanoma.Semantic proximity Read ↗

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.Semantic proximity Read ↗

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.Semantic proximity Read ↗

Targeting BRAF in advanced melanoma: a first step toward manageable disease.Semantic proximity Read ↗

Multiple murine BRaf<sup>V600E</sup> melanoma cell lines with sensitivity to PLX4032Semantic proximity Read ↗

Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells.Semantic proximity Read ↗

B-Raf inhibition in conjunctival melanoma cell lines with PLX 4720.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.